0.16Open0.16Pre Close0 Volume30 Open Interest2.00Strike Price0.00Turnover88.24%IV2.13%PremiumDec 20, 2024Expiry Date0.12Intrinsic Value100Multiplier28DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type-0.5484Delta0.8694Gamma7.52Leverage Ratio-0.0032Theta-0.0009Rho-4.12Eff Leverage0.0021Vega
Akebia Therapeutics Stock Discussion
3 mins ago
Akebia Therapeutics Signs Commercial Supply Contract With Leading Dialysis Organization to Enable Access to Vafseo® (Vadadustat) for Patients on Dialysis! Expected to be available in USA in January 2025
Designed to help dialysis organizations incorporate new treatments into their practices, TDAPA provides two years of reimbursement in addition to the ESRD bundled rate
A HCPCS code has also been assig...
Akebia Therapeutics Inc - Contract Enables Prescription of Vafseo for Dialysis Patients From Jan 2025
No comment yet